Novo Nordisk First Quarter 2025 Earnings: EPS Beats Expectations

Simply Wall St · 05/08 05:18

Novo Nordisk (CPH:NOVO B) First Quarter 2025 Results

Key Financial Results

  • Revenue: kr.78.1b (up 20% from 1Q 2024).
  • Net income: kr.29.0b (up 14% from 1Q 2024).
  • Profit margin: 37% (down from 39% in 1Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: kr.6.54 (up from kr.5.70 in 1Q 2024).
earnings-and-revenue-growth
CPSE:NOVO B Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Novo Nordisk EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.1%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Denmark.

The company's shares are up 2.7% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Novo Nordisk, and understanding these should be part of your investment process.